Avalo Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Avalo Therapeutics, Inc. (AVTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are AVTX insiders buying or selling?
In the last 12 months, Avalo Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 23 sales ($8.5M) — net selling of $8.5M. Since April 2018, Trabud has recorded 129 Form 4 filings for AVTX: 103 buys ($56.4M) and 26 sells ($11.7M).
Source: SEC EDGAR Form 4
Key Statistics (April 2018 – Sep 18, 2026)
Total Form 4 filings
129
SEC EDGAR
Insider filers
21
Insider buys (103)
$56.4M
Insider sells (26)
$11.7M
Insider sentiment
Net buyingNet insider flow of $44.7M in net buying since April 2018, and $8.5M in net selling over the last 12 months.
Recent AVTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 12.4K | $16.33 | $202.4K | SEC ↗ |
| Sep 11, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 10.2K | $17.62 | $179.5K | SEC ↗ |
| Sep 1, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 679 | $20.00 | $13.6K | SEC ↗ |
| Aug 19, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 72.7K | $19.94 | $1.5M | SEC ↗ |
| Aug 19, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 1.0K | $20.00 | $20.0K | SEC ↗ |
| Aug 12, 2026 | Jennifer Riley | Chief Strategy Officer | Sale | 2.7K | $19.59 | $52.0K | SEC ↗ |
| Aug 12, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 679 | $20.00 | $13.6K | SEC ↗ |
| Jul 29, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 1.0K | $20.00 | $20.0K | SEC ↗ |
| Jul 2, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 4.7K | $20.00 | $93.1K | SEC ↗ |
| Jun 25, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 1.4K | $18.00 | $26.1K | SEC ↗ |
| Jun 1, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 679 | $16.00 | $10.9K | SEC ↗ |
| May 19, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 3.0K | $18.76 | $56.3K | SEC ↗ |
| May 11, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 18.6K | $24.12 | $448.8K | SEC ↗ |
| May 7, 2026 | Paul Varki | Chief Legal Officer | Sale | 75.1K | $20.17 | $1.5M | SEC ↗ |
| May 7, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 47.0K | $20.19 | $948.7K | SEC ↗ |
| May 7, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 108.2K | $20.61 | $2.2M | SEC ↗ |
| May 7, 2026 | Mitchell Chan | Director | Sale | 3.2K | $22.88 | $72.5K | SEC ↗ |
| May 1, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 16.9K | $13.16 | $222.6K | SEC ↗ |
| Apr 8, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 4.0K | $18.01 | $71.5K | SEC ↗ |
| Apr 3, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sale | 16.0K | $16.96 | $270.6K | SEC ↗ |
| Apr 3, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 679 | $16.00 | $10.9K | SEC ↗ |
| Mar 18, 2026 | Mittie Doyle | Chief Medical Officer | Sale | 25.5K | $16.15 | $411.6K | SEC ↗ |
| Nov 17, 2025 | Jonathan Goldman | Director | Sale | 11.4K | $14.33 | $162.9K | SEC ↗ |
| Nov 14, 2024 | June Sherie Almenoff | Director | Purchase | 1.0K | $12.75 | $12.7K | SEC ↗ |
| Jun 28, 2023 | Steven Boyd | 10% Owner | Sale | 3.7M | $0.59 | $2.2M | SEC ↗ |
Showing the 25 most recent of 129 Form 4 filings for Avalo Therapeutics, Inc..
Most active AVTX insiders
- Steven Boyd58 filings
- Caissa Capital Management ltd.14 filings
- Mittie Doyle12 filings
- Christopher Ryan Sullivan11 filings
- James Archie Harrell Jr7 filings
Ask anything about AVTX insider activity
Use Trabud's AI agent to query Avalo Therapeutics, Inc.'s Form 4 history in plain English — "Show me AVTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentAVTX insider trading FAQ
Are Avalo Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Avalo Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 23 sales ($8.5M) — net selling of $8.5M. Since April 2018, Trabud has recorded 129 Form 4 filings for AVTX: 103 buys ($56.4M) and 26 sells ($11.7M). Over the full record that is net buying of $44.7M.
How many insiders trade AVTX stock?
21 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Avalo Therapeutics, Inc.. The most recent filing was accepted on Sep 18, 2026.
Where does Trabud get AVTX insider trading data?
All AVTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.